Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Statement

14 May 2021 07:00

RNS Number : 5928Y
Sabre Insurance Group PLC
14 May 2021
 

 

14 May 2021

SABRE INSURANCE GROUP PLC

 

Trading Update

 

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides an update on trading for the period to 30 April 2021 ahead of its AGM later this morning.

- Continued focus on prioritising underwriting profitability over volume, with price increases materially ahead of the market

- Overall, volumes for the first quarter of the year are in line with our expectations

- Gross written premium for the four months to 30 April 2021 was £46.0m (four months to 30 April 2020: £54.6m)

- Continued strong organic capital generation with a solvency coverage ratio of 171% post-dividend as at 31 March 2021 (31 December 2020: 155%)

- Too early to identify meaningful market quote volume increases as lockdown eases, however:

- throughout April, volumes were ahead of the comparative period in 2020

- clear visibility on premium outturn for the full year remains limited at this point due to numerous intertwined regulatory, market and COVID impacts

- combined ratio for the financial year is expected to be within the target range of 70% to 80%

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"Volumes through Q1 were in line with our expectations, during which we continued to execute our strategy of focusing on profitability over volume. Alongside that, we continue to investigate and implement new rating factors and potential new, complementary product offerings which will help drive disciplined and profitable volume growth in future periods.

While we are still in the very early stages of an easing in the lockdown restrictions, through April we have started to see some increase in our premium levels, and the policy count has enjoyed modest growth. Premiums in April were 14.6% higher than the same period last year, with the weekly run-rate increasing relative to 2020 towards the end of the month and into the first week of May. This is despite us being consistent with regard to our pricing discipline and against a backdrop of low quote volumes across the market.

Looking forward, we remain confident that volumes will increase as the number of drivers and car sales increase. We also expect that - in due course - the FCA pricing review, changes to small bodily injury claims ("whiplash reforms") and ongoing claims inflation will drive some competitors to increase prices materially.

Our claims performance and organic capital generation was strong, and we remain confident of providing an attractive dividend for the year, possibly through the utilisation of our robust capital range. While short term visibility remains limited, we remain confident that our agility and tried-and-tested strategy will deliver a strong result for the year.

Finally, we are delighted to have appointed Matthew Wright as our new Chief Actuary after a near 12-month transition period and seven years with Sabre. We are confident Matt will be able to further enhance our market leading pricing capabilities."

 

Investor enquiries

01306 747272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Tulchan Communications

sabre@tulchangroup.com

James Macey White

David Allchurch

Giles Kernick

The Sabre Insurance Group plc LEI number is 2138006RXRQ8P8VKGV98

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDUSXBDGBX
Date   Source Headline
12th Apr 20214:41 pmRNSNotice of AGM
7th Apr 20212:16 pmRNSDirector/PDMR Shareholding
30th Mar 20211:56 pmRNSDirector/PDMR Shareholding
26th Mar 20218:24 amRNSDirector/PDMR Shareholding
16th Mar 20217:03 amRNSFinal Results
12th Mar 20217:00 amRNSNotice of Results
11th Mar 202110:37 amRNSDirector/PDMR Shareholding
1st Mar 20213:56 pmRNSHolding(s) in Company
23rd Feb 202110:40 amRNSNotice of Results
11th Feb 202110:28 amRNSDirector/PDMR Shareholding
1st Feb 202110:02 amRNSHolding(s) in Company
12th Jan 202110:53 amRNSDirector/PDMR Shareholding
8th Jan 20219:44 amRNSHolding(s) in Company
11th Dec 20201:31 pmRNSDirector/PDMR Shareholding
3rd Dec 20207:56 amRNSHolding(s) in Company
3rd Dec 20207:00 amRNSBoard Appointment
27th Nov 20204:42 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
11th Nov 202012:07 pmRNSDirector/PDMR Shareholding
6th Nov 202011:39 amRNSHolding(s) in Company
6th Nov 202010:55 amRNSHolding(s) in Company
27th Oct 20203:47 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSDirector/PDMR Shareholding
13th Oct 20209:42 amRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSTrading Statement
11th Sep 202010:07 amRNSDirector/PDMR Shareholding
3rd Sep 20204:13 pmRNSDirector/PDMR Shareholding
1st Sep 20202:23 pmRNSDirector/PDMR Shareholding
28th Aug 202012:02 pmRNSPrice Monitoring Extension
27th Aug 202011:32 amRNSDirector/PDMR Shareholding
19th Aug 20207:00 amRNSDirectorate Change
12th Aug 20203:50 pmRNSHolding(s) in Company
11th Aug 20201:15 pmRNSDirector/PDMR Shareholding
10th Aug 20204:00 pmRNSHolding(s) in Company
6th Aug 202012:14 pmRNSDirector/PDMR Shareholding - Correction
6th Aug 202010:11 amRNSDirector/PDMR Shareholding
6th Aug 20209:32 amRNSDirector/PDMR Shareholding
3rd Aug 202012:54 pmRNSDirector/PDMR Shareholding
28th Jul 20207:02 amRNSBoard appointment
28th Jul 20207:00 amRNSHalf-year Report
14th Jul 20204:13 pmRNSHolding(s) in Company
13th Jul 202012:51 pmRNSDirector/PDMR Shareholding
30th Jun 20201:33 pmRNSDirector/PDMR Shareholding
11th Jun 20201:59 pmRNSDirector/PDMR Shareholding
10th Jun 20209:57 amRNSDirector/PDMR Shareholding - Correction
4th Jun 20209:49 amRNSDirector/PDMR Shareholding
29th May 20203:39 pmRNSDirector/PDMR Shareholding
29th May 202012:37 pmRNSDirector/PDMR Shareholding
21st May 202012:17 pmRNSResult of AGM
21st May 20207:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.